* severe covid-19 is defined by one or more of the following: * blood oxygen saturation ≤ 90% * partial pressure of arterial oxygen to fraction of inspired oxygen ratio \< 300 * lung infiltrates ≥ 50% within 24 to 48 hours * life-threatening covid-19 is defined as one or more of the following: * respiratory failure * septic shock * multiple organ dysfunction or failure * weight less than 45 kg. * pregnant or breast-feeding females * subjects on dialysis or with creatinine clearance \< 45 ml/min * subjects who need antiviral administration due to severe viral diseases other than covid-19, such as hiv, hepatitis b, and hepatitis c * existing division of microbiology and infectious disease toxicity scale for determining the severity of adverse events grade 3 or greater. * uncontrolled seizure disorder * subjects with reflux esophagitis after chronic pancreatitis and gastrectomy surgery. * patients with reflux esophagitis after surgery. * known allergy to artemisia annua or camostat mesilate. * currently receiving any study medications for other indications. * concurrent use of medication that would cause moderate or severe due to drug-drug interactions with study medication. specifically: * patients receiving artemisia annua tea may not be currently taking strong inducers of cyp2a6, including phenobarbital and rifampin. * receipt in the 12 hours prior to enrollment, or planned administration during the 14-day study period that treating clinicians feel cannot be substituted for another medication, of any of the following: amiodarone; cimetidine; dofetilide; phenobarbital; phenytoin; or sotalol. * cancer patients receiving active immunosuppressive treatment cannot be enrolled unless they are on a treatment holiday with no antineoplastic treatment with 3 weeks of enrollment. * patients with genetic problems such as galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption * subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening * enrollment on other experimental therapies for covid-19. * inability to receive enteral medications * patients with psychiatric illness/social situations that would limit compliance with study requirements. * subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening * any other condition that in the opinion of the treating physician justifies exclusion from the study.

* severe covid-19 is defined by one or more of the following: * blood oxygen saturation ≤ 90% * partial pressure of arterial oxygen to fraction of inspired oxygen ratio \< 300 * lung infiltrates ≥ 50% within 24 to 48 hours * life-threatening covid-19 is defined as one or more of the following: * respiratory failure * septic shock * multiple organ dysfunction or failure * weight less than 45 kg. * pregnant or breast-feeding females * subjects on dialysis or with creatinine clearance \< 45 ml/min * subjects who need antiviral administration due to severe viral diseases other than covid-19, such as hiv, hepatitis b, and hepatitis c * existing division of microbiology and infectious disease toxicity scale for determining the severity of adverse events grade 3 or greater. * uncontrolled seizure disorder * subjects with reflux esophagitis after chronic pancreatitis and gastrectomy surgery. * patients with reflux esophagitis after surgery. * known allergy to artemisia annua or camostat mesilate. * currently receiving any study medications for other indications. * concurrent use of medication that would cause moderate or severe due to drug-drug interactions with study medication. specifically: * patients receiving artemisia annua tea may not be currently taking strong inducers of cyp2a6, including phenobarbital and rifampin. * receipt in the 12 hours prior to enrollment, or planned administration during the 14-day study period that treating clinicians feel cannot be substituted for another medication, of any of the following: amiodarone; cimetidine; dofetilide; phenobarbital; phenytoin; or sotalol. * cancer patients receiving active immunosuppressive treatment cannot be enrolled unless they are on a treatment holiday with no antineoplastic treatment with 3 weeks of enrollment. * patients with genetic problems such as galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption * subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening * enrollment on other experimental therapies for covid-19. * inability to receive enteral medications * patients with psychiatric illness/social situations that would limit compliance with study requirements. * subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening * any other condition that in the opinion of the treating physician justifies exclusion from the study.

- severe covid-19 is defined by one or more of the following: - blood oxygen saturation ≤ 90% - partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300 - lung infiltrates ≥ 50% within 24 to 48 hours - life-threatening covid-19 is defined as one or more of the following: - respiratory failure - septic shock - multiple organ dysfunction or failure - weight less than 45 kg. - pregnant or breast-feeding females - subjects on dialysis or with creatinine clearance < 45 ml/min - subjects who need antiviral administration due to severe viral diseases other than covid-19, such as hiv, hepatitis b, and hepatitis c - existing division of microbiology and infectious disease toxicity scale for determining the severity of adverse events grade 3 or greater. - uncontrolled seizure disorder - subjects with reflux esophagitis after chronic pancreatitis and gastrectomy surgery. - patients with reflux esophagitis after surgery. - known allergy to artemisia annua or camostat mesilate. - currently receiving any study medications for other indications. - concurrent use of medication that would cause moderate or severe due to drug-drug interactions with study medication. specifically: - patients receiving artemisia annua tea may not be currently taking strong inducers of cyp2a6, including phenobarbital and rifampin. - receipt in the 12 hours prior to enrollment, or planned administration during the 14-day study period that treating clinicians feel cannot be substituted for another medication, of any of the following: amiodarone; cimetidine; dofetilide; phenobarbital; phenytoin; or sotalol. - cancer patients receiving active immunosuppressive treatment cannot be enrolled unless they are on a treatment holiday with no antineoplastic treatment with 3 weeks of enrollment. - patients with genetic problems such as galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption - subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening - enrollment on other experimental therapies for covid-19. - inability to receive enteral medications - patients with psychiatric illness/social situations that would limit compliance with study requirements. - subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening - any other condition that in the opinion of the treating physician justifies exclusion from the study.

- severe covid-19 is defined by one or more of the following: - blood oxygen saturation ≤ 90% - partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300 - lung infiltrates ≥ 50% within 24 to 48 hours - life-threatening covid-19 is defined as one or more of the following: - respiratory failure - septic shock - multiple organ dysfunction or failure - weight less than 45 kg. - pregnant or breast-feeding females - subjects on dialysis or with creatinine clearance < 45 ml/min - subjects who need antiviral administration due to severe viral diseases other than covid-19, such as hiv, hepatitis b, and hepatitis c - existing division of microbiology and infectious disease toxicity scale for determining the severity of adverse events grade 3 or greater. - uncontrolled seizure disorder - subjects with reflux esophagitis after chronic pancreatitis and gastrectomy surgery. - patients with reflux esophagitis after surgery. - known allergy to artemisia annua or camostat mesilate. - currently receiving any study medications for other indications. - concurrent use of medication that would cause moderate or severe due to drug-drug interactions with study medication. specifically: - patients receiving artemisia annua tea may not be currently taking strong inducers of cyp2a6, including phenobarbital and rifampin. - receipt in the 12 hours prior to enrollment, or planned administration during the 14-day study period that treating clinicians feel cannot be substituted for another medication, of any of the following: amiodarone; cimetidine; dofetilide; phenobarbital; phenytoin; or sotalol. - cancer patients receiving active immunosuppressive treatment cannot be enrolled unless they are on a treatment holiday with no antineoplastic treatment with 3 weeks of enrollment. - patients with genetic problems such as galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption - subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening - enrollment on other experimental therapies for covid-19. - inability to receive enteral medications - patients with psychiatric illness/social situations that would limit compliance with study requirements. - subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening - any other condition that in the opinion of the treating physician justifies exclusion from the study.